Clinical Cancer Research, Vol 2, Issue 9 1559-1564, Copyright © 1996 by American Association for Cancer Research

ARTICLES

Correlation of chromosome 17p loss with clinical outcome in medulloblastoma

SM Emadian, JD McDonald, SC Gerken and D Fults
Departments of Neurosurgery and Oncological Sciences and Program in Human Molecular Biology and Genetics, University of Utah Health Sciences Center, Salt Lake City, Utah 84132, USA.

Medulloblastomas are primitive neuroectodermal tumors that arise in the cerebella of children. Cytogenetic and loss of heterozygosity (LOH) studies have shown that deletions on the short arm of chromosome 17 occur in 25-50% of cases, suggesting that loss of a tumor suppressor gene located on 17p plays a role in the genesis or progression of medulloblastoma. We report here on an LOH analysis of 21 patients with medulloblastoma using markers for 15 polymorphic loci previously ordered on chromosome 17 by meiotic break point mapping. Although the frequency of LOH in our patients (48%) was consistent with previous reports, our maps showed much larger deletions, the smallest spanning a 38-cM genetic distance distal to marker UT49 (D17S731). Survival analysis did not show a significant association between LOH on 17p and survival, although the sample size was too small to rule out a difference of less than 10-fold. Clinical risk factors were better prognostic indicators than LOH, with significantly prolonged survival in patients free of craniospinal metastasis following gross total tumor resection.

This article has been cited by other articles:

				K. C. Lo, C. Ma, B. N. Bundy, S. L. Pomeroy, C. G. Eberhart, and J. K. Cowell Gain of 1q Is a Potential Univariate Negative Prognostic Marker for Survival in Medulloblastoma Clin. Cancer Res., December 1, 2007; 13(23): 7022 - 7028. [Abstract] [Full Text] [PDF]

				E. Pan, M. Pellarin, E. Holmes, I. Smirnov, A. Misra, C. G. Eberhart, P. C. Burger, J. A. Biegel, and B. G. Feuerstein Isochromosome 17q Is a Negative Prognostic Factor in Poor-Risk Childhood Medulloblastoma Patients Clin. Cancer Res., July 1, 2005; 11(13): 4733 - 4740. [Abstract] [Full Text] [PDF]

				K. Neben, A. Korshunov, A. Benner, G. Wrobel, M. Hahn, F. Kokocinski, A. Golanov, S. Joos, and P. Lichter Microarray-Based Screening for Molecular Markers in Medulloblastoma Revealed STK15 as Independent Predictor for Survival Cancer Res., May 1, 2004; 64(9): 3103 - 3111. [Abstract] [Full Text] [PDF]

				B. R. Rood, H. Zhang, D. M. Weitman, and P. H. Cogen Hypermethylation of HIC-1 and 17p Allelic Loss in Medulloblastoma Cancer Res., July 1, 2002; 62(13): 3794 - 3797. [Abstract] [Full Text] [PDF]

				J Nicholson, C Wickramasinghe, F Ross, J Crolla, and D Ellison Imbalances of chromosome 17 in medulloblastomas determined by comparative genomic hybridisation and fluorescence in situ hybridisation Mol. Pathol., December 1, 2000; 53(6): 313 - 319. [Abstract] [Full Text]

				J. A. Biegel Cytogenetics and molecular genetics of childhood brain tumors Neuro-oncol, April 1, 1999; 1(2): 139 - 151. [Abstract] [PDF]